Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.715 -0.145 (-3.76%)

Streaming Delayed Price Updated: 10:27 AM EDT, Aug 31, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	270,035
Open	3.770
Bid (Size)	3.710 (2,500)
Ask (Size)	3.720 (400)
Prev. Close	3.860
Today's Range	3.710 - 3.800
52wk Range	2.530 - 5.450
Shares Outstanding	65,837,894
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

August 10, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

August 03, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	+7.4%	+7.4%
1 Month	+19.5%	+19.5%
3 Month	+23.0%	+23.0%
6 Month	-25.3%	-25.3%
1 Year	+14.7%	+14.7%

More News

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

June 12, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

May 28, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 07, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

April 28, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

Via MarketMinute

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

March 27, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

February 26, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

February 23, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

November 25, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Posts Narrower Q3 2025 Loss, Advances Gene Therapy Pipeline ↗

November 06, 2025

Via Chartmill

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

November 06, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗

November 04, 2025

Via Benzinga

ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 23, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock ↗

October 14, 2025

Via Benzinga

Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗

October 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 14, 2025

Via Benzinga

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

October 14, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy ↗

October 03, 2025

Via Stocktwits

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗

September 04, 2025

Via Benzinga

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

August 28, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Rocket Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Rocket Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Rocket Pharmaceuticals, Inc. - Common Stock trade on?

Rocket Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock is RCKT on the Nasdaq Stock Market

What is the current price of Rocket Pharmaceuticals, Inc. - Common Stock?

The current price of Rocket Pharmaceuticals, Inc. - Common Stock is 3.715

When was Rocket Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Rocket Pharmaceuticals, Inc. - Common Stock was at 08/31/26 10:27 AM ET

What is the market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock is 244.59M

How many shares of Rocket Pharmaceuticals, Inc. - Common Stock are outstanding?

Rocket Pharmaceuticals, Inc. - Common Stock has 245M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.